retatrutide clinical trials results NEW Phase 3 Trial Review Triple hormone receptor agonist retatrutide

avoid rechallenge if serious outcomes or clear recurrence occurs

2017 Sep 21 [cited 2018 Oct 17];377(12):114355

2.1.2.3 Insurance coverage - Ensure that insurance plans provide coverage for GLP-1 RAs for adolescents who meet the established clinical criteria, thereby minimizing bureaucratic barriers to access

Whether participants took 5 mg or 15 mg, roughly one in twenty experienced noticeable hair shedding

Start by swapping one staple, such as white bread or white rice, for a whole-grain alternative like brown rice, wheat-based pasta, a few times a week

The trial found significant weight loss across all treatment groups, with the highest dose producing the largest effect